Mark Rivvers News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The FINANCIAL -- The RECOVERY trial has demonstrated that baricitinib reduces the risk of death when given to hospitalised patients with severe COVID-19. Baricitinib is an anti-inflammatory treatment normally used to treat rheumatoid arthritis. According to UKRI, the benefit was in addition to those of dexamethasone and tocilizumab, two other anti-inflammatory treatments that have previously beenThe FINANCIAL -- The RECOVERY trial has demonstrated that baricitinib reduces the risk of death when given to hospitalised patients with severe COVID-19. Baricitinib is an anti-inflammatory treatment n...

Oxford Researchers say a drug used to treat rheumatoid arthritis, reduces the risk of people in hospital with severe Covid-19 from dying.

The benefit was in addition to those of dexamethasone and tocilizumab, two other anti-inflammatory treatments which have previously been shown to reduce the risk of death in these patients.The University of Oxford-led RECOVERY trial has been testing

An anti-inflammatory for rheumatoid arthritis can cut Covid death risk by about a fifth.

The benefit was on top of that provided by dexamethasone and tocilizumab, researchers found.